Johnson & Johnson Statement on its COVID-19 Vaccine Following CDC ACIP Meeting

NEW BRUNSWICK, N.J., December 16, 2021 – Johnson & Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson & Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi], [vii], [viii], [ix]“The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” says Mathai Mammen M.D., Ph.D., Global Head, Janssen Research & Development, LLC, Johnson & Johnson. “We appreciate today’s discussion and look forward to working with the CDC on next steps. In addition, we strongly support education and generating awareness of rare events, such as Thrombosis with Thrombocytopenia Syndrome (TTS) and how to effectively manage it.”Given its strong durability, the Johnson & Johnson COVID-19 vaccine remains an important choice in the U.S. for people who can’t or won’t return for multiple vaccinations or who would remain unvaccinated without an alternative to the mRNA vaccines. With ease of storage and transport, it offers a vital tool, and in many populations, includ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news